TransMedics Group (NASDAQ:TMDX) Reaches New 52-Week High at $132.96

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $132.96 and last traded at $130.10, with a volume of 49462 shares. The stock had previously closed at $132.65.

Analyst Ratings Changes

TMDX has been the subject of several recent analyst reports. Canaccord Genuity Group upped their target price on shares of TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. TD Cowen increased their price target on TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Morgan Stanley lifted their price objective on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Piper Sandler reissued an “overweight” rating and set a $120.00 target price (up from $95.00) on shares of TransMedics Group in a research note on Wednesday, May 1st. Finally, JPMorgan Chase & Co. lifted their price target on shares of TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and an average target price of $119.00.

TransMedics Group Trading Up 1.2 %

The stock has a market cap of $4.24 billion, a price-to-earnings ratio of -378.74 and a beta of 1.87. The business has a 50-day simple moving average of $89.25 and a two-hundred day simple moving average of $79.26. The company has a debt-to-equity ratio of 3.18, a quick ratio of 8.76 and a current ratio of 9.72.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The business had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. During the same quarter last year, the firm earned ($0.08) earnings per share. The firm’s revenue for the quarter was up 132.9% compared to the same quarter last year. As a group, research analysts forecast that TransMedics Group, Inc. will post 0.62 EPS for the current year.

Insider Activity at TransMedics Group

In other news, insider Tamer I. Khayal sold 776 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $90.00, for a total transaction of $69,840.00. Following the sale, the insider now owns 14,375 shares in the company, valued at approximately $1,293,750. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Tamer I. Khayal sold 776 shares of TransMedics Group stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $90.00, for a total transaction of $69,840.00. Following the completion of the transaction, the insider now owns 14,375 shares in the company, valued at $1,293,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen Gordon sold 15,000 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $74.01, for a total value of $1,110,150.00. Following the completion of the sale, the chief financial officer now owns 23,299 shares in the company, valued at approximately $1,724,358.99. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 295,889 shares of company stock valued at $31,623,584. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC raised its stake in TransMedics Group by 42.5% in the third quarter. FMR LLC now owns 4,714,870 shares of the company’s stock valued at $258,139,000 after purchasing an additional 1,407,171 shares in the last quarter. Eventide Asset Management LLC lifted its holdings in shares of TransMedics Group by 1,271.7% during the 3rd quarter. Eventide Asset Management LLC now owns 925,356 shares of the company’s stock worth $50,663,000 after acquiring an additional 857,895 shares during the period. Mackenzie Financial Corp acquired a new stake in shares of TransMedics Group during the 4th quarter worth approximately $35,804,000. Wasatch Advisors LP bought a new position in TransMedics Group in the first quarter valued at approximately $32,162,000. Finally, Bank of New York Mellon Corp raised its position in TransMedics Group by 91.4% during the third quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock valued at $41,615,000 after purchasing an additional 363,012 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.